Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Biochem Biophys Res Commun ; 518(3): 605-609, 2019 10 20.
Article in English | MEDLINE | ID: mdl-31445709

ABSTRACT

In the stomach, Sonic Hedgehog (Shh) is highly expressed in gastric parietal cells, and acts as a morphogen in early development of the organ. Here, we found that the cleaved N-terminal fragment of Shh (Shh-N) was abundantly expressed in hog gastric vesicles derived from the apical membrane of parietal cells. Interestingly, Shh-N recombinant significantly decreased K+-dependent ATP-hydrolyzing activity, which is sensitive to an inhibitor of H+,K+-ATPase (SCH28080), in hog gastric tubulovesicles and membrane fractions of the H+,K+-ATPase-expressing cells. In the living cells, Shh-N recombinant inhibited the SCH28080-sensitive 86Rb+-uptake. Together, Shh-N may directly bind to extracellular side of H+,K+-ATPase, and negatively regulates the pump activity. This is the first report to explore non-morphogenic property of Shh on ion transporters.


Subject(s)
H(+)-K(+)-Exchanging ATPase/metabolism , Hedgehog Proteins/metabolism , Parietal Cells, Gastric/metabolism , Animals , Cell Line , Humans , Hydrolysis , Rabbits , Recombinant Proteins/metabolism , Swine
2.
Chem Pharm Bull (Tokyo) ; 66(9): 896-900, 2018.
Article in English | MEDLINE | ID: mdl-30175749

ABSTRACT

To investigate the inhibitory effect of a commercial proton pump inhibitor (lansoprazole) on the gastric proton pump H+,K+-ATPase in vitro, we used orally disintegrating (OD) tablets including original brand-name and generic tablets. In the course of the development of generic products, dissolution and clinical tests are necessary to ensure their bioequivalence to the original brand-name products; by contrast, there is almost no opportunity to demonstrate their activity in vitro. This study initially compared the similarity of the dissolution of test generic tablets with that of the original brand-name tablets. The dissolution tests for 15 and 30-mg lansoprazole tablets found their dissolution properties were similar. Subsequently, the dissolution media were sampled and then their effects on the H+,K+-ATPase activity were measured using tubulovesicles prepared from the gastric mucosa of hogs. We confirmed that the inhibitory effects of the generic tablets on H+,K+-ATPase activity were consistent with those of the original brand-name tablets. Furthermore, lansoprazole contents in each tablet estimated from their inhibitory effects were in good agreement with their active pharmaceutical ingredient content. To our knowledge, this is the first technical report to compare the in vitro biochemical activity of lansoprazole OD tablets between the original brand-name and generic commercial products.


Subject(s)
Adenosine Triphosphatases/antagonists & inhibitors , Lansoprazole/pharmacology , Proton Pump Inhibitors/pharmacology , Adenosine Triphosphatases/metabolism , Administration, Oral , Animals , Drugs, Generic , Humans , Lansoprazole/chemistry , Proton Pump Inhibitors/chemistry , Solubility , Stomach/cytology , Stomach/enzymology , Swine , Tablets , Therapeutic Equivalency
SELECTION OF CITATIONS
SEARCH DETAIL